CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE
The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.
1 . A controlled release formulation of dronedarone comprising dronedarone, controlled release polymer and pharmaceutically acceptable excipients.
2 . The controlled release formulation of claim 1 wherein the controlled release polymer may be selected from water soluble polymer, water insoluble polymer, waxy material or combination thereof.
3 . The controlled release formulation of claim 2 comprising water soluble polymer may be selected from alkyl celluloses such as methyl cellulose; hydroxyalkyl celluloses, for example, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxybutyl cellulose; hydroxyalkyl alkyl celluloses such as hydroxyethyl methyl cellulose and hydroxypropyl methyl cellulose; sodium or calcium carboxymethyl cellulose, methyl ethyl cellulose, ethylhydroxy ethylcellulose, carboxyalkyl cellulose esters; carbomers; glycerol fatty acid esters, sorbitan esters, lecithins, other natural, semi-synthetic, or synthetic di-, oligo-, and polysaccharides such as galactomannans, tragacanth, agar, guar gum, gum arabic, pectin, acacia, karaya, locust bean gum, xanthan gum, pullulan, collagen, casein, carrageenan, aligns, polycarbophil, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, scleroglucan and polyfructans, maltodextrin; methacrylate copolymers; polyvinyl alcohol; polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate; combinations of polyvinyl alcohol and polyvinylpyrrolidone; and polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, carboxyvinyl polymers, sodium alginate, sodium hyluronate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, gelatin, starch, crosslinked starch, microcrystalline cellulose, ceratonia, chitin, poly(hydroxyalkyl methacrylate), polyvinyl alcohol having a low acetate residual, a swellable mixture of agar and carboxymethyl cellulose, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone and mixtures and blends thereof and pharmaceutically acceptable excipients.
4 . The controlled release formulation of claim 2 comprising water insoluble polymer selected from cellulose acylate; cellulose ethyl ether; cellulose diacylate; cellulose triacylate; cellulose acetate; cellulose diacetate; cellulose triacetate; mono-, di- and tricellulose alkan, mono-, di- and tricellulose aroyl; ethyl cellulose; cellulose acetate; cellulose acetate butyrate; cellulose acetate phthalate; cellulose acetate trimellitate; glyceryl monooleate; glyceryl monostearate; glyceryl palmitostearate; polyvinyl acetate phthalate; hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate succinate; poly(alkyl methacrylate); poly(vinyl acetate); poly vinyl alcohols; polyacrylamide derivatives ammonio methacrylate copolymers, poly acrylic acid and poly acrylate and methacrylate copolymers, aminoacryl-methacrylate copolymer, polyvinyl acetaldiethylamino acetate, copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene, polyacrylamides, polyox(polyethylene oxides), diesters of polyglucan, cellulose butyrate, cellulose propionate, shellac, chitosan, oleyl alcohol, zein, hydrogenated castor oil and the like and pharmaceutically acceptable excipients.
5 . The controlled release formulation of claim 2 comprising waxy material selected from carnauba wax; beeswax; chinese wax; spermaceti; lanolin; bayberry wax; white wax; yellow wax; candelilla wax; microcrystalline wax; castor wax; esparto wax; Japan wax; jojoba oil; cotton seed oil, corn oil, hydrogenated cotton seed oil, ouricury wax; rice bran wax; ceresin waxes; montan wax; ozokerite; peat waxes; paraffin wax; polyethylene waxes; and polyglycerol fatty acid esters and pharmaceutically acceptable excipients.
6 . A controlled release formulation of dronedarone comprising
(1) Dronedarone and pharmaceutically acceptable excipients and
(2) Controlled release coating.
7 . The controlled release formulation of claim 6 wherein the controlled release coating comprises of controlled release polymer.
8 . The controlled release formulation of claim 6 wherein the controlled release polymers includes hydrophilic polymers, hydrophobic polymers or waxes.
9 . The controlled release formulation of claim 6 wherein the controlled release coating may be functional coating, moisture barrier coating, enteric polymeric coating, sustained release coating and the like.
10 . A controlled release formulation of dronedarone comprising
(1) Dronedarone and pharmaceutically acceptable excipients and
(2) One or more coating optionally comprising dronedarone.
11 . The controlled release formulation of claim 10 wherein one or more coating is selected from controlled release or enteric or immediate release.
12 . The controlled release formulation of claim 10 wherein the coating comprises of water soluble polymer, water insoluble polymer, waxy material or combination thereof as exemplified in example 13 or 14.